Acute Congestive Heart Failure

NCT ID: NCT01885403

Last Updated: 2015-09-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to determine the feasibility of collecting respiratory parameters during recompensation following ADHF (Acute Decompensated Heart Failure)with non-invasive measurements. This could lead to a better understanding of how respiratory parameters may change during re-compensation therapy and could also be a comfortable method for patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is designed as a single-center, open, interventional, observational study according to clause §23b of the German Medical Device Act (MPG). The study will recruit 50 patients suffering from cardiogenic pulmonary congestion and edema including ambulant patients and patients of intensive care.

We will investigate whether respiratory parameters during re-compensation are related to the therapy effects and changes in pulmonary congestion status. This study will collect data in an observational and clinical setting in the re-compensation phase of ADHF.

Correlation between measured lung and respiratory parameters and standard clinical parameters characterizing stages of re-compensation will be undertaken. Standard clinical parameters may include diuretics and other cardiac medication dose frequency, weight, heart rate, respiratory rate, chest x-rays (when routinely performed), symptoms such as shortness of breath or fatigue, biomarkers such as brain natriuretic peptide (BNP), stroke volume, cardiac output, and oxygen requirements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Decompensated Heart Failure (ADHF) Acute Cardiogenic Pulmonary Edema (ACPE)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Respiratory Parameters Measurements

Group Type EXPERIMENTAL

non-invasive respiratory parameter measurements

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

non-invasive respiratory parameter measurements

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Philips Respironics BiPAP Synchrony, Bioimpedance ImpediMed- SFB7

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females, ages 18-75
2. Able and willing to provide written informed consent or not able to give informed consent because of mechanical respiration
3. Diagnosis of acute or chronic decompensated heart failure with pulmonary congestion or edema
4. Systolic blood pressure \>80 mm Hg at time of enrollment
5. Resting pulse oximetry (SpO2) at the time of enrollment of at least 88% at 21% iron oxides (FeO2)
6. Agreement to be measured with the study devices according to study protocol by patient or legal representative
7. Left ventricular ejection fraction (LVEF) \< 40% in 3D- Echocardiography

Exclusion Criteria

1. Active participation in another interventional research study
2. Surgery of the upper airway, nose, sinus or middle ear within the last 90 days
3. Major medical or psychiatric condition that would interfere with the demands of the study or the ability to complete the study. For example, severe unstable chronic lung disease such as obstructive (FEV1/FVC ≤ 30%), or restrictive (FVC \< 50% predicted) lung disease, neuromuscular disease, cancer, or renal failure
4. Unable to use PAP therapies due to physical issues (e.g. facial structural abnormalities) or cognitive issues (e.g. dementia)
5. Participants in whom positive airway pressure (PAP) therapy is medically contraindicated.
6. Uncontrolled hypertension (systolic ≥200 mm Hg/diastolic ≥120 mm Hg)
7. Pregnancy
8. Lactation
9. Implanted pacemaker / Cardiac Resynchronization Therapy (CRT) / implantable cardioverter-defibrillator (ICD) except for Medtronic devices with Opti Vol Algorithm
10. Incompetent patients or patients who, in the judgment of the investigator, are too unstable or are otherwise not capable of performing study procedures
11. Post-partum cardiomyopathy
12. Hypertrophic
13. Primary mitral valve stenosis
14. Patients requiring more than 50% supplemental oxygen or patients requiring more than 4 lpm oxygen
15. Patients with persistent ventricular arrhythmias (Premature ventricular coupling, periods of ventricular tachycardia)
16. Patients chronically classified (prior to admission) as New York Heart Association (NYHA) Class IV or American Heart Association Class D heart failure
17. Patients with glomerular filtration rate (GFR) \<30 or obligatory dialysis
18. Resting respiratory rate \>30 breaths per minute
19. Patients requiring mechanical ventilation or patients with an artificial airway (endotracheal or tracheostomy tube)
20. Patients with carbon monoxide toxicity
21. Patients with severe sepsis (defined as also an organ dysfunction due to an infection according to the Guidelines of the German Association of Sepsis, February 2010)
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Philips Technology Aachen Germany

UNKNOWN

Sponsor Role collaborator

RWTH Aachen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jörg Schröder, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Cardiology, Pneumology, Angiology and Intensive Care, Internal Medicine I (MK I), University Hospital Aachen (UKA)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital of Aachen, Department of Cardiology

Aachen, Northrhine-Westfalia, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jörg Schröder, MD

Role: CONTACT

+4924180 ext. 89391

Sigrid Gloeggler, M.Sc.

Role: CONTACT

+4924180 ext. 80202

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jörg Schröder, MD

Role: primary

+4924180 ext. 89391

Sigrid Gloeggler, M.Sc.

Role: backup

+4924180 ext. 80202

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CTC-A 12-117

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

New Model of Care in Heart Failure
NCT03476590 COMPLETED NA